Merck & Co., Inc.

- The company expects a onetime charge related to the acquisition of Terns, increasing R&D expense by approximately $5.8 billion or $2 per share. - The assumed cost of financing for the Terns acquisition is expected to negatively impact EPS by approximately $0.12 in the current year. - Other expense is expected to rise primarily due to financing related to recent business development transactions. - The company has raised revenue and EPS guidance for the full year, now expecting revenue between $65.8 billion and $67 billion. - There is mention of maintaining the ability within a strong balance sheet to pursue additional science-driven, value-enhancing business development transactions going forward. - The company is on pace for approximately $3 billion of share repurchases this year as previously guided. - No explicit details about new fundraising through debt or equity beyond the financing assumptions for the Terns acquisition are mentioned.

- Merck plans to continue prioritizing investments in their business to drive near- and long-term growth, including new product launches and pipeline development. - The company remains committed to business development as a key strategic lever, exemplified by the recent acquisition of Terns Pharmaceuticals. - The Terns acquisition will result in a one-time R&D charge of approximately $5.8 billion and ongoing EPS impact, reflecting investment to advance TERN-701 and associated pipeline assets. - Merck maintains strong balance sheet capacity to pursue additional science-driven, value-enhancing transactions in the future. - The company is actively investing in AI and data capabilities through multiyear partnerships with Google Cloud, Tempus AI, and Mayo Clinic to accelerate pipeline innovation. - Ongoing investments are also made in expanding commercial operating structures and leadership to support execution and growth. - Share repurchases are on pace for approximately $3 billion in 2026, indicating capital returned to shareholders alongside strategic investments.

- Merck expects 2026 revenue between $65.8 billion and $67 billion, implying 1%-3% growth including ~1% positive foreign exchange impact. - Continued growth driven by oncology (KEYTRUDA family up 8%), animal health (up 6%), and new product launches. - Over 20 new product launches underway, collectively targeting a commercial opportunity exceeding $70 billion by mid-decade. - Key upcoming regulatory milestones and approvals expected to further bolster growth. - Planned acquisition of Terns Pharmaceuticals to add a promising CML asset (TERN-701) expected to contribute to long-term pipeline and growth. - Investments in AI and data partnerships aim to accelerate pipeline productivity and innovation. - Animal health segment growth supported by new products like NUMELVI for allergic dermatitis in dogs. - Share repurchases planned at approximately $3 billion in 2026 to return capital and support share value.

- 2026 full-year revenue guidance narrowed to $65.8 billion - $67 billion, implying 1% - 3% growth, including ~1% positive foreign exchange impact. - EPS guidance raised to $5.04 - $5.16, with a roughly $0.10 positive foreign exchange contribution; excludes proposed Terns acquisition impact. - One-time $9 billion Cidara Therapeutics acquisition charge impacted recent quarter earnings with a $3.62 per share negative effect. - Upcoming acquisition of Terns Pharmaceuticals expected to create a $5.8 billion one-time R&D charge (+$2.35 per share) and an EPS headwind of approximately $0.12 in 2026. - Management emphasizes investments in growth drivers, new product launches, and pipeline advancement to drive near- and long-term growth. - On pace for ~$3 billion in share repurchases in 2026, supporting shareholder returns. - Confidence expressed in delivering a potential commercial opportunity exceeding $70 billion by mid-decade from new growth drivers.

The provided transcript does not explicitly detail Merck's current or expected orderbook or pending orders. However, key points related to demand and sales outlook include: - Total revenue grew 5% to $16.3 billion, driven by oncology and animal health. - Strong launch progress with over 20 new products underway, each with "blockbuster potential." - WINREVAIR reported $525 million in global sales, with 1,600+ new U.S. prescriptions. - Expect ENFLONSIA shipments to increase in the second half of the year due to RSV season. - OHTUVAYRE sales at $131 million impacted by reimbursement changes but prescription trends recovering. - Animal health sales up 6%, driven by new launches and pricing. - Management expects robust demand from newly launched products and pipeline assets, supporting revenue guidance of $65.8 billion–$67 billion for 2026. No specific orderbook or pending orders data disclosed.